New collaborative offers mass vaccination sites an essential network to support 200 million vaccinations in 100 days
| BOSTON, April 20, 2021 /PRNewswire/ -- Ariadne Labs has launched the Global Mass Vaccination Site Collaborative to facilitate a rapid information exchange in order to broaden the impact of and safely deliver more COVID-19 vaccinations globally. The collaborative currently has 50 members representing more than 12 mass vaccination sites from across the country. It’s a critical time for mass vaccination sites to refine their approach, and share successes, challenges and solutions. The speed of the development and evaluation of SARS-CoV-2 vaccines has far exceeded expectations, but many leaders face ongoing uncertainty in ensuring the delivery of the vaccines with speed, scale, and equity. Mass vaccination sites—like stadiums, arenas, and convention centers—are proving essential and scalable, able to safely deliver thousands of vaccines in a single day. Mass vaccination site leaders have encountered various challenges, including information system platforms, insurance reimbursements, logistics, patient flow, and indoor vs outdoor considerations. Lower vaccine confidence and significant inequity in vaccine distribution affect people of color and other communities that have been disproportionately affected by COVID-19. These challenges continue to plague vaccine delivery. The Global Mass Vaccination Site Collaborative is led by Eric Goralnick, MD, MS, Mass General Brigham Medical Director for the CIC Health run sites in Massachusetts, Medical Director of Emergency Preparedness at Brigham and Women’s Hospital, and Associate Faculty at Ariadne Labs. “As the U.S. and other countries increase access to vaccination, it is a critical time for mass vaccination sites to refine their approach, and share successes, challenges and solutions in a rapid, seamless, and open format to benefit all,” said Goralnick. Throughout the COVID-19 pandemic, Ariadne Labs has developed scalable, systems-level solutions to support clinicians, patients, the general public, and public health decision makers. Drawing on the organization’s research, frontline clinical care experience, background in health systems innovations, and emergent public health threats, Ariadne Labs has developed solutions to allocate, distribute, verify, and generate demand for the vaccines. “Mass vaccination sites have proven to be a vital piece of the COVID-19 vaccine distribution puzzle,” said Atul Gawande, MD, MPH, Chair and Founder of Ariadne Labs, and co-founder of CIC Health, which manages three mass vaccination sites in Massachusetts. “As cases and hospitalizations rise, so does the urgency of getting as many people as possible vaccinated as quickly as possible.” “We must advocate for faster distribution of vaccines worldwide. Not stopping the spread of COVID-19 everywhere could mean additional mutations, potentially more deadly and difficult to control,” said Michelle A. Williams, Ariadne Labs Advisory Board member and dean of the faculty at the Harvard T.H. Chan School of Public Health. “We have already seen this start to play out, making widespread vaccination all the more important.” “Minimizing the threat of COVID-19 requires an equitable and robust response from clinical and public health systems,” said Asaf Bitton, MD, MPH, Executive Director of Ariadne Labs. “As experts in public health, frontline clinical care, health systems, and health equity, Ariadne Labs is uniquely positioned to support mass vaccination sites that have proved crucial in protecting the public during this stage of the pandemic.” Initial Global Mass Vaccination Site Collaborative members include (in alphabetical order):
About Ariadne Labs: Media Contact:
SOURCE Ariadne Labs |
View original content:
